Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8062935 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL24704618 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL21032192 | 0.74 | CFTR (0.38) | MAPTNPC1 | |
| SCHEMBL21031910 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL5415041 | 0.73 | SMN1; SMN2 (0.56) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL21031913 | 0.73 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD | |
| SCHEMBL8058184 | 0.72 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL21031911 | 0.71 | KDM4E (0.44) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL8058129 | 0.70 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 | |
| SCHEMBL29070076 | 0.69 | PTPRC (0.42) | ALDH1A1KDM4EHSD17B10ALOX15CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489233-B1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248770-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | NR3C2, CRHR2, TPH2 | ALDH1A1 1366/4885KDM4E 4467/4885HSD17B10 901/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | ALDH1A1 1366/4885KDM4E 4467/4885HSD17B10 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.